Please login to the form below

Not currently logged in

ALK Abelló's John Tarplee joins Adherium

Becomes business development SVP for Europe

Adherium John TarpleeMelbourne-based Adherium Limited has appointed John Tarplee to the newly-created position of senior vice president of business development, Europe.

Tarplee will responsible for leading market development and partnering for the digital health technology firm's European business, which was established in conjunction with his appointment and is based in Guildford, UK.

He brings over 30 years of sales and market expansion expertise, most recently in the role of senior vice president at Danish immunotherapy company ALK Abelló where he oversaw its commercial operations and geographical expansion strategy.

Prior to this, Tarplee has held several management level roles at Sanofi, including business unit director UK, and he has also worked for Abbott Laboratories and Fisons Pharmaceuticals.

Garth Sutherland, chief executive officer of Adherium, said: “I am delighted to welcome John to the team and to be establishing a formal base of operations on the ground in Europe.

“Attracting a senior business development executive of this calibre to expand our footprint and market presence is a strong endorsement of our technology and business model.”

8th April 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...